#160389

Tin Tungstate Nanoparticles Beta-SnWO4 small molecule (tool compound)

Please Enter Your Email ID
Email ID

Cat. #160389

Tin Tungstate Nanoparticles Beta-SnWO4 small molecule (tool compound)

Cat. #: 160389

Sub-type: Nanoparticle

Availability: Please enquire for quantities and pricing

Application: Used to treat tumours in BALB/C mice orthotopically inoculated with the 4T1 breast cancer cell line. Reduced lymph node metastases.Killed 4T1 cells in vitro.

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Claus Feldmann

Institute: Karlsruhe Institute of Technology

Tool Details
Handling
Target Details
Application Details
References

Tool Details

*FOR RESEARCH USE ONLY

  • Tool name: Tin Tungstate Nanoparticles Beta-SnWO4 small molecule (tool compound)
  • Cancer: Breast cancer;Skin cancer
  • Cancers detailed: Breast cancer;Colon;Esophageal;Gastric;Skin cancer
  • Research fields: Cancer;Metabolism
  • Tool sub type: Nanoparticle
  • Primary target: Near-surface tumours
  • Description: Tin Tungstate nanoparticles act as photosensitizers for photodynamic tumor therapy of near-surface tumors via reiterated 5 min blue-light LED illumination.
  • Application: Used to treat tumours in BALB/C mice orthotopically inoculated with the 4T1 breast cancer cell line. Reduced lymph node metastases.Killed 4T1 cells in vitro.
  • Additional notes: "The nanoparticulate inorganic photosensitizer β-SnWO4 is suggested for photodynamic therapy (PDT) of near-surface tumors via reiterated 5 min blue-light LED illumination. β-SnWO4 nanoparticles are obtained via water-based synthesis and comprise excellent colloidal stability under physiological conditions and high biocompatibility at low material complexity. Antitumor and antimetastatic effects were investigated with a spontaneously metastasizing (4T1 cells) orthotopic breast cancer BALB/c mouse model. Besides protamine-functionalized β-SnWO4 (23 mg/kg of body weight, in PBS buffer), chemotherapeutic doxorubicin was used as positive control (2.5 mg/kg of body weight, in PBS buffer) and physiological saline (DPBS) as a negative control. After 21 days, treatment with β-SnWO4 resulted in a clearly inhibited growth of the primary tumor (all tumor volumes below 3 cm3) as compared to the doxorubicin and DPBS control groups (volumes up to 6 cm3). Histological evaluations of lymph nodes and lungs as well as the volume of ipsilateral lymph nodes show a remarkable antimetastatic effect being similar to chemotherapeutic doxorubicin butaccording to blood countsat significantly reduced side effects. On the basis of low material complexity, high cytotoxicity under blue-light LED illumination at low dark and long-term toxicity, β-SnWO4 can be an interesting addition to PDT and the treatment of near-surface tumors, including skin cancer, esophageal/gastric/colon tumors as well as certain types of breast cancer." From Seidl et al 2016, ACS Nano, 10, 3149−3157.

Handling

  • Shipping conditions: Dry Ice

Target Details

  • Primary target: Near-surface tumours

Application Details

  • Application: Used to treat tumours in BALB/C mice orthotopically inoculated with the 4T1 breast cancer cell line. Reduced lymph node metastases.Killed 4T1 cells in vitro.

References

  • Seidl et al. 2016. ACS Nano. 10(3):3149-57. PMID: 26894966.
  • Ungelenk et al. 2014. Chem Commun (Camb). 50(50):6600-3. PMID: 24824575.
  • Ungelenk et al. 2012. Chem Commun (Camb). 48(63):7838-40. PMID: 22735092.